HPD, occurring in about 9% of advanced cancer patients and 29% of head and neck cancer patients treated with PD-1/PD-L1 inhibitors, may result from abnormal immune responses or immune dysregulation in the tumor microenvironment (23, 24). This evidence concerns the gene CD274 and neoplasm.